Status:
COMPLETED
Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors
Lead Sponsor:
University of California, Davis
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Unspecified Adult Solid Tumor, Protocol Specific
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the grow...
Detailed Description
OBJECTIVES: Primary * Determine the safety and feasibility of 2 different schedules of lapatinib ditosylate when administered with vinorelbine ditartrate in patients with advanced solid tumors. Sec...
Eligibility Criteria
Inclusion
- Cytologically or histologically proven advanced solid tumors for which there is no known standard therapy available or are not eligible for standard therapy because of their performance status, or have progressed after no more than 2 prior chemotherapy regimens for metastatic disease.
- Measurable or evaluable disease. Disease in previously irradiated sites is considered measurable if there is clear disease progression following radiation therapy.
- 18 years of age or older.
- Zubrod performance status of 0-2.
- Estimated survival of at least 3 months.
- Any prior chemotherapy must have been completed at least 4 weeks prior to start of this protocol and all side effects (except alopecia) resolved to grade 1 or less. Any prior radiation must have been completed at least 2 weeks prior to start of therapy. For prior mitomycin chemotherapy a 6-week interval is required. Patients must have completed prior trastuzumab at least 4 weeks prior to start of protocol therapy.
- Adequate renal function
- Adequate liver function
- Pretreatment granulocyte count of \>1500/mm3 and platelet count of \>100 000/mm3.
- Cardiac ejection fraction within the institutional range of normal as measured by 2-D echocardiogram or MUGA scan.
- Asymptomatic treated brain metastasis may be included if they are neurologically stable and have been off steroids and anticonvulsants for at least 4 weeks.
- All patients must give informed consent.
- Able to take and retain oral medication.
- Patients of reproductive potential must agree to use an effective contraceptive method
Exclusion
- Patients may not have previously received lapatinib, vinorelbine or any other EGFR-1 targeted agent. Prior trastuzumab is allowed.
- Females cannot be pregnant or breastfeeding
- Symptomatic brain metastasis or still requiring steroids and anticonvulsants may not participate.
- Pre-existing neuropathy \> grade 2 may not participate.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, will be excluded.
- History of other diseases, metabolic dysfunction, physical examination finding or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the patient at high risk from treatment complications.
- Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, or prior surgical procedures affecting absorption.
- HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with lapatinib.
- Patients requiring oral anticoagulants are eligible provided there is appropriate close INR monitoring is in place. If medically appropriate and treatment available, the investigator may also consider switching these patients to LMW heparin, where an interaction with lapatinib is not expected.
- Adherence to the requirements for concomitant medications classified as CYP3A4 inducers or inhibitors, or gastric pH modifiers
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00389922
Start Date
December 1 2005
End Date
December 1 2011
Last Update
April 19 2012
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
City of Hope Comprehensive Cancer Center
Duarte, California, United States, 91010-3000
2
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, United States, 90089-9181
3
University of California Davis Cancer Center
Sacramento, California, United States, 95817
4
Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109-1023